ITRM vs. TTPH, NBRV, SPRO, ORMP, ASMB, PRPH, ANIX, VSTM, CMRX, and IOBT
Should you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Tetraphase Pharmaceuticals (TTPH), Nabriva Therapeutics (NBRV), Spero Therapeutics (SPRO), Oramed Pharmaceuticals (ORMP), Assembly Biosciences (ASMB), ProPhase Labs (PRPH), Anixa Biosciences (ANIX), Verastem (VSTM), Chimerix (CMRX), and IO Biotech (IOBT). These companies are all part of the "medical" sector.
Iterum Therapeutics (NASDAQ:ITRM) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 42.3% of Tetraphase Pharmaceuticals shares are held by institutional investors. 5.6% of Iterum Therapeutics shares are held by insiders. Comparatively, 5.7% of Tetraphase Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Iterum Therapeutics has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500.
Iterum Therapeutics has higher earnings, but lower revenue than Tetraphase Pharmaceuticals. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Tetraphase Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics has a net margin of 0.00% compared to Tetraphase Pharmaceuticals' net margin of -798.18%. Tetraphase Pharmaceuticals' return on equity of -210.86% beat Iterum Therapeutics' return on equity.
Tetraphase Pharmaceuticals received 246 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote while only 62.44% of users gave Iterum Therapeutics an outperform vote.
In the previous week, Iterum Therapeutics had 1 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 1 mentions for Iterum Therapeutics and 0 mentions for Tetraphase Pharmaceuticals. Iterum Therapeutics' average media sentiment score of 1.89 beat Tetraphase Pharmaceuticals' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the media.
Iterum Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 412.82%. Given Iterum Therapeutics' higher probable upside, equities analysts plainly believe Iterum Therapeutics is more favorable than Tetraphase Pharmaceuticals.
Summary
Iterum Therapeutics and Tetraphase Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Iterum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iterum Therapeutics Competitors List
Related Companies and Tools
